Gene Therapy Lyfgenia denied as non-formulary by Aetna?

Aetna's specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Aetna Non-Formulary Denial for Lyfgenia — Why It Happens and How to Appeal

Lyfgenia (lovotibeglogene autotemcel) is an FDA-approved gene therapy for sickle cell disease. Gene therapies are frequently not listed on a health plan's standard drug formulary because they are one-time, specialty-administered products rather than outpatient pharmacy fills. A non-formulary denial does not mean coverage is impossible — it means you must pursue a formulary exception, and federal law gives you that right.

## Why Non-Formulary Denials Happen for Gene Therapy

Most health plan formularies are designed around recurring pharmacy medications. A gene therapy like Lyfgenia is typically billed under the medical benefit (not the pharmacy benefit) and administered in a hospital or specialized center. Non-formulary denials can arise from benefit routing errors (the claim was evaluated under the pharmacy benefit instead of the medical benefit), formulary lags (the product was recently approved and not yet added), or a genuine formulary gap with no exception pathway flagged. All three are contestable.

## Federal Appeal Framework

• Internal appeal / formulary exception: File a formulary exception request and, simultaneously, a standard internal appeal — both within 180 days of denial. Aetna must respond within 30 days (standard) or 72 hours (urgent).
• External review (ACA §2719): After final internal denial, request independent external review, generally within approximately 4 months. IROs can overturn non-formulary denials when the formulary exclusion is not clinically justified.
• ERISA §503: For employer-sponsored plans, full-and-fair review rights apply.
• Expedited review: Request in writing if delay poses serious health risk.

## Documentation to Gather

1. Benefit routing clarification: Confirm whether the claim was evaluated under the pharmacy benefit or the medical benefit. Request this in writing from Aetna. Gene therapy is almost always a medical benefit product. 2. Prescriber medical-necessity letter: A letter confirming FDA approval, the specific sickle cell disease indication, and that no formulary alternative exists that is clinically equivalent for this patient. 3. FDA prescribing label: Demonstrates that Lyfgenia is not a standard outpatient pharmacy product but a specialized one-time infusion requiring hospital administration. 4. Aetna CPB and formulary documents: Request the specific formulary tier structure and CPB applied. Identify whether a formulary exception pathway or medical-benefit route is available. 5. Diagnosis and severity records: Supporting the medical necessity of Lyfgenia over any treatments that may be listed on the formulary.

## Criteria-Mapping Structure

| Non-Formulary Issue | Your Response | |---|---| | Not on pharmacy formulary | Clarify: medical-benefit product, not pharmacy-dispensed | | No formulary exception filed | File exception simultaneously with appeal | | Alternative formulary therapy suggested | Prescriber letter on why alternatives are not clinically equivalent | | Formulary lag post-approval | Cite FDA approval date vs. formulary update schedule |

Non-formulary denials for gene therapy frequently resolve when the claim is correctly routed to the medical benefit. Start by confirming the benefit routing with Aetna before investing significant effort in a formulary exception appeal.